Physician

Amarendra Kumar Neppalli, MD

According to 2025 Medicare claims, Amarendra Neppalli, MD (NPI: 1992948442) practices hematology/oncology in the Washington, DC-MD market, with the plurality of this provider's patient population coming from The District, DC. This provider's primary affiliated billing organization is MEDICAL FACULTY ASSOCIATES, INC (NPI: 1417990581; TIN: 522220700) and primary practice location at 20037-3201. Neppalli is affiliated with the PBACO Holding, LLC (ACO ID: A1001), MUSC Health Alliance, LLC (ACO ID: A5535), and Accountable Care Organization of Advocate Aurora Health, LLC (ACO ID: D0260), participating under both the MSSP and REACH models.

Neppalli's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 113 traditional Medicare patients, billed 16,490 HCPCS/CPT codes, and received $374,476 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 101 prescription claims across 25 beneficiaries totaling $561,035 in drug costs, led by Revlimid (Lenalidomide). 2021 DME data shows 24 claims. Open Payments data shows 7 records totaling $26,464. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $24,846 to $374,476. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $86,824 and ending at $561,035. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	160	374	$24,846
2017	254	1,098	$73,550
2018	221	1,053	$73,981
2019	205	793	$57,699
2020	198	1,252	$89,739
2021	161	989	$69,760
2022	78	674	$42,154
2023	79	11,815	$249,321
2024	113	16,490	$374,476

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	60	221	$86,824
2016	73	354	$905,018
2017	87	614	$1,682,932
2018	96	564	$1,495,672
2019	105	539	$2,158,735
2020	65	288	$718,388
2021	42	77	$491,790
2022	12	23	$26,969
2023	29	154	$502,249
2024	25	101	$561,035

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	15	$2,303
2018	N/R	25	$2,443
2019	N/R	27	$2,197
2020	N/R	12	$74,340
2021	N/R	24	$157,054
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	17	28	$156
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	41	44	$110
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	31	71	$95
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	24	66	$67
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	29	49	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	12	336	$227,032
Acyclovir	Acyclovir	15	790	$266
Dexamethasone	Dexamethasone	14	507	$218

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$1,926	Janssen Scientific Affairs, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$24,538	Janssen Research & Development, LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amarendra Kumar Neppalli, MD?

Tedicare shows public-source Medicare data for Amarendra Kumar Neppalli, MD (NPI 1992948442), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amarendra Kumar Neppalli, MD have ACO affiliation data?

Amarendra Kumar Neppalli, MD is shown with ACO affiliation data for PBACO Holding, LLC (MSSP, ACO ID A1001), MUSC Health Alliance, LLC (MSSP, ACO ID A5535), and Accountable Care Organization of Advocate Aurora Health, LLC (REACH, ACO ID D0260).

What billing organization is linked to Amarendra Kumar Neppalli, MD?

Amarendra Kumar Neppalli, MD is linked to MEDICAL FACULTY ASSOCIATES, INC (billing NPI 1417990581) in the available physician profile data.

Does Amarendra Kumar Neppalli, MD have Open Payments data?

Amarendra Kumar Neppalli, MD has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.